Paul Hartmann AG (STU:PHH2) ROCE %: 13.12% (As of Dec. 2025)

What is Paul Hartmann AG ROCE %?

Paul Hartmann AG STU:PHH2 +0.49% 64 ROCE % is 13.12% as of Dec. 2025. GuruFocus rates STU:PHH2 with a GF Score™ of 64/100 and a GF Value™ of €229.60 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Paul Hartmann AG's annualized ROCE % for the quarter that ended in Dec. 2025 was 13.12%.

Paul Hartmann AG (STU:PHH2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Paul Hartmann AG ROCE % Related Terms

Paul Hartmann AG ROCE % Historical Data

* Premium members only.

The historical data trend for Paul Hartmann AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paul Hartmann AG ROCE % Chart

Paul Hartmann AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

10.51

4.57

4.32

9.20

7.65

Paul Hartmann AG Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															7.98	6.22	12.03	2.35	13.12

64GF Score

Paul Hartmann AG STU:PHH2

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Paul Hartmann AG ROCE % Calculation

Paul Hartmann AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	125.914	/	( ( (2097.867 - 465.595)	+	(2161.147 - 501.357) )	/ 2 )
	=	125.914	/	( (1632.272	+	1659.79)	/ 2 )
	=	125.914	/	1646.031
	=	7.65 %

Paul Hartmann AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	213.81	/	( ( (2150.27 - 551.522)	+	(2161.147 - 501.357) )	/ 2 )
	=	213.81	/	( ( 1598.748	+	1659.79 )	/ 2 )
	=	213.81	/	1629.269
	=	13.12 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 13.12% mean?

Paul Hartmann AG (STU:PHH2) has a ROCE % of 13.12% as of Dec. 2025.

Is Paul Hartmann AG's ROCE % too high?

Paul Hartmann AG's current ROCE % is 13.12%. The Medical Devices & Instruments industry median ROCE % is 2.23. Paul Hartmann AG's value of 13.12% is 488.3% above this industry median. Overall, Paul Hartmann AG has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Paul Hartmann AG's ROCE % compare to ISRG and BDX?

Paul Hartmann AG's ROCE % of 13.12% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Paul Hartmann AG's value of 13.12% is 488.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current ROCE % of 13.12% is 488.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current ROCE % is 13.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Paul Hartmann AG stock overvalued right now?

Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €229.60, compared to a current price of €205.00 — trading 10.7% below its estimated fair value. The current ROCE % is 13.12% and 488.3% above the Medical Devices & Instruments industry median of 2.23. Paul Hartmann AG's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current ROCE % is 13.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?

Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued. The current stock price of €205.00 is trading 10.7% below its estimated GF Value™ of €229.60. GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.

Key valuation signals for STU:PHH2:

ROCE %: 13.12%
GF Value™: €229.60 vs. price of €205.00 (10.7% below fair value)
GF Score™: 64/100 with 4 warning signs
Industry Position: 488.3% above the Medical Devices & Instruments median

No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Paul Hartmann AG Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XTER:GXI XTER:AFX XTER:1SXP ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543 XPAR:DIM COO SOLV OCSE:COLO B NZSE:FPH ALGN BAX

Other Exchanges PHH2:Germany

Address Paul-Hartmann-Strasse 12, Heidenheim, DEU, 89522

Website http://www.hartmann.info

Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.

64GF Score

Get the complete analysis for STU:PHH2

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€205.00

Price

€229.60

GF Value

View STU:PHH2 Analysis

See ROCE % data for all stocks →